AR and pachyonychia congenita: Over the years, several drugs changed the PC therapeutic scenario: second-generation androgen receptor targeting therapies (ARTAs) such as enzalutamide, abiraterone, apalutamide and darolutamide represented an innovative cornerstone of PC therapies [53].